Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size

Dose-Dense MVAC With Pegfilgrastim Support in Subjects With Muscle-Invasive Urothelial Carcinoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Beth Israel Deaconess Medical Center
Brigham and Women's Hospital
Amgen
Information provided by (Responsible Party):
Toni Choueiri, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier:
NCT00808639
First received: December 15, 2008
Last updated: February 9, 2015
Last verified: February 2015
History of Changes
Results First Received: January 14, 2014  
Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study;   Intervention Model: Single Group Assignment;   Masking: Open Label;   Primary Purpose: Treatment
Conditions: Bladder Cancer
Muscle-invasive Bladder Cancer
Interventions: Drug: Methotrexate
Drug: Doxorubicin
Drug: vinblastine
Drug: cisplatin
Drug: Pegfilgrastim

  Participant Flow
  Hide Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Dose Dense MVAC No text entered.

Participant Flow:   Overall Study
    Dose Dense MVAC  
STARTED     39  
COMPLETED     38 [1]
NOT COMPLETED     1  
One patient went off treatment due to di                 1  
[1] One patient went off treatment due to disease progression before surgery.



  Baseline Characteristics
  Hide Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
  Description
Dose Dense MVAC

Methotrexate: intravenously 30mg/m2 over 30 minutes

Doxorubicin: intravenously 30mg/ms over 15 minutes

vinblastine: intravenously 3mg/m2 over 30 minutes

cisplatin: intravenously 70mg/m2 in 1 liter NS with 12.5gm Mannitol over 2 hours after vinblastine completion

Pegfilgrastim: Given subcutaneously 24 hours after last chemotherapy dose

Baseline Measures
    Dose Dense MVAC  
Number of Participants  
[units: participants]
 		  39  
Age  
[units: years]
Median ( Full Range ) 		  57  
  ( 43 to 76 )  
Gender  
[units: participants]
 		 
Female     11  
Male     28  
Race (NIH/OMB)  
[units: participants]
 		 
American Indian or Alaska Native     0  
Asian     0  
Native Hawaiian or Other Pacific Islander     0  
Black or African American     0  
White     39  
More than one race     0  
Unknown or Not Reported     0  
Region of Enrollment  
[units: participants]
 		 
United States     39  



  Outcome Measures
  Show All Outcome Measures

1.  Primary:   Number of Patients Achieving Pathologic Response   [ Time Frame: After completion of 4 cycles of chemotherapy with pegfilgrastim support (cycle length 2 weeks) ]
  Show Outcome Measure 1

2.  Secondary:   Number of Patients Experiencing Febrile Neutropenia   [ Time Frame: After completion of 4 cycles of chemotherapy with pegfilgrastim support (cycle length 2 weeks) ]
  Show Outcome Measure 2

3.  Secondary:   Number of Patients Experiencing Surgery-related Toxicity   [ Time Frame: Surgery + 30 days ]
  Show Outcome Measure 3


  Serious Adverse Events
  Show Serious Adverse Events


  Other Adverse Events
  Show Other Adverse Events


  Limitations and Caveats
  Hide Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information
  Hide More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Toni Choueiri, MD
Organization: Dana-Farber Cancer Institute
phone: 617-632-5456
e-mail: toni_choueiri@dfci.harvard.edu


No publications provided by Dana-Farber Cancer Institute

Publications automatically indexed to this study:


Responsible Party: Toni Choueiri, MD, Dana-Farber Cancer Institute
ClinicalTrials.gov Identifier: NCT00808639     History of Changes
Other Study ID Numbers: 08-208
Study First Received: December 15, 2008
Results First Received: January 14, 2014
Last Updated: February 9, 2015
Health Authority: United States: Institutional Review Board